Year in Review 2024 - Transformative FDA Approvals in Precision Onco…

Oncology 2024 Year in Review

V. Subbiah

ASH 2024 Summary: Myeloma Highlights and Impact on Practice

2024 ASH Annual Meeting Insights Hub

H. Hashmi

ASH 2024 Review: Key Multiple Myeloma Abstracts

Cleveland Clinic Taussig Cancer Institute

N. Callander

ASH 2024 Summary: Highlights in Adult ALL and Implications for Pract…

2024 ASH Annual Meeting Insights Hub

R. Cassaday

ASH 2024 Summary: Multiple Myeloma Highlights and Clinical Implicati…

2024 ASH Annual Meeting Insights Hub

S. Al Hadidi

2024 Updates on Management of DLBCL

Louisville Hematology Highlights

J. Leonard

Multiple Myeloma: Not as Simple as "CRAB" Anymore

Fred Hutch 14th Annual Comprehensive Hematology & Oncology Review Course

R. Banerjee

Multiple Myeloma: A Journey From Pharaoh's Times to 2024

Houston Methodist

S. Ganguly

Debate: Using BCMA CAR-T in Early vs Late Line R/R MM Treatment

Louisville Hematology Highlights

K. Patel, S. Usmani

ASH 2024 Review: Key Updates in Non-Hodgkin Lymphoma

Cleveland Clinic Taussig Cancer Institute

P. Caimi

Treating Patients With DLBCL Who Are Not Eligible for CAR-T Therapy

Remy Dulery

Sequencing Cellular Therapy and Bispecific Antibodies in DLBCL

Megan Melody

ASH 2024 Summary: Highlights in Ph- ALL

2024 ASH Annual Meeting Insights Hub

F. Haddad

Cellular Therapy in 2024: What, Why, When, Who… and Where Are We Goi…

University of Colorado Department of Medicine

J. Gutman

ESMO 2024 Summary: Highlights in Heme Malignancies

2024 ESMO Annual Meeting Insights Hub

M. Gomes da Silva

ASH 2024 Insights: Outcomes With Bispecific Antibodies Post-CAR T-Ce…

2024 ASH Annual Meeting Insights Hub

M. Melody

CAR-T Strategies and Clinical Considerations for R/R MM

Moffitt Cancer Center

K. Patel

2024 Updates on Emerging & Current Treatment of Multiple Myeloma

Indy Hematology Review

K. Anderson

The Future of NDMM Treatment: Ongoing Trials and Key ASH 2024 Oral A…

University of Miami Sylvester Comprehensive Cancer Center

O. Landgren

Advances in Multiple Myeloma 2024: From Bench to Bedside

Dana-Farber Cancer Institute

K. Anderson